Alto Ingredients, Inc.

ALTO
About the company

Alto Ingredients, Inc. produces, distributes, and markets specialty alcohols, renewable fuel, and essential ingredients in the United States. The company operates in three segments: Marketing and Distribution, Pekin Campus Production, and Western Production.

Country: United StatesPrice: $3.66Market Cap: $283.9M

Investment snapshot

35%positive consensus
Scored 1d ago

Positive

6

BUY / PASS

Neutral / negative

1 / 9

NEUTRAL / FAIL

Median fair value

$1.58

-56.8% vs price

Models with upside

1 / 17

Positive margin of safety

Strongest signal

9 of 12 pass — Buffett, Lynch and Asness object

Key risk

14 of 16 flag ALTO's profitability — Graham, Buffett, Lynch +11 more

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictPASSFAILFAILFAIL · Rank #1139 (Top 36.8%)PASSFAILPASSFAILFAILFAILPASSPASSFAILBUYFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety-8.3%+29.5%N/AN/AN/AN/A-293.5%-131.6%N/AN/A-293.5%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-13

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-06

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-06

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage75% pass✓ 12✗ 3▾

    9 of 12 pass — Buffett, Lynch and Asness object

    LT Debt vs Net Current AssetsLT Debt $54.5M vs NCA $119.6M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.21, IC: 3.2x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.21
    ✓Lynch< 0.33
    Cash - Long-term Debt$-30.9M
    ✗LynchPositive preferred
    LT Debt / Total Assets Change23.14% -> 16.21%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities3.39
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.21
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.21
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=3.2x, D/EBITDA=1.1x
    ✓MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.21
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.2124; #1721/4210 (top 40.9%)
    ✗AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Profitability13% pass✓ 12✗ 23▾

    14 of 16 flag ALTO's profitability — Graham, Buffett, Lynch +11 more

    Positive EPS (10 years)5/23 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)7/23 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-6.2%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)0.8% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$34.0M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)P/E 22.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR-28.4%
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE18.6%
    ✓Lynch> 15%
    EBIT / Enterprise Value8.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=8.1%, ROC=8.7%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets3.43%
    ✓PiotroskiROA > 0
    ROA Change YoY-14.69% -> 3.43% (delta: +18.12%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=3.41%, ROA=3.43%
    ✗PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY1.0% -> 3.8%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue5.2%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity18.6%
    ✓Dreman> 12%
    Margin of SafetyP/E=22.9x, P/B=1.2x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-10.3% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency7/17 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue2.7%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity18.6%
    ✓Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-2.0% (2023) -> 0.8% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 1.3% -> 3.8%, operating margin -2.0% -> 0.8%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+17.89%; #301/6340 (top 4.7%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+13.87%; #2502/3702 (top 67.6%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity+18.58%; #873/5226 (top 16.7%)
    ✓AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0868; #3303/5884 (top 56.1%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR-28.4% over 4 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years2/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Growth13% pass✓ 2✗ 11▾

    7 of 8 flag ALTO's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)P/E 22.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR-28.4%
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 1.7% vs Rev: 4.1%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency7/17 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-8.4%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 1.3% -> 3.8%, operating margin -2.0% -> 0.8%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR0.5%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR-28.4% over 4 years
    ✗Neff7%-20% annualized
  • Valuation15% pass✓ 8✗ 20▾

    11 of 13 flag ALTO's valuation — Graham, Lynch, Greenblatt +8 more

    Price / Book Value per Share1.2x
    ✓Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio1.2x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)P/E 22.9x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value8.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=8.1%, ROC=8.7%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS22.9x
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)21.4x
    ✗Dreman< 8x
    Valuation ReasonablenessP/E=22.9x, OE Yield=12.0%
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=22.9x, FCF Yield=3.0%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=22.9x, P/B=1.2x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share32.7x
    ✗Ackman<= 25
    Price vs. Trailing Low407% of trailing low ($0.90)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+17.89%; #301/6340 (top 4.7%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.9632; #1554/6449 (top 24.1%)
    ✓AsnessTop 30% of eligible cross-section
    Price / Diluted EPS22.9x
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share1.19x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-21.6%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+3.3821; #736/5247 (top 14.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+13.12%; #493/4519 (top 10.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-23.67%; #4147/6202 (top 66.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Cash Flow20% pass✓ 4✗ 8▾

    8 of 10 flag ALTO's cash flow — Buffett, Piotroski, Dreman +5 more

    Free Cash Flow Proxy$34.0M
    ✗BuffettPositive and growing
    FCF Positive and Growing$37.3M
    ✓LynchPositive and growing
    Operating Cash Flow$13.2M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=3.41%, ROA=3.43%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)21.4x
    ✗Dreman< 8x
    P/E or FCF YieldP/E=22.9x, FCF Yield=3.0%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive7/16 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap13.2%
    ✓Ackman>= 4%
    Price / FCF per Share32.7x
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency10/16 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$37.3M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+13.12%; #493/4519 (top 10.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Valuation models20% pass✓ 1✗ 4▾

    Models split on ALTO at $3.66 — fair values range $0.93–$5.19

    Graham fair value$3.38
    ✗Graham-8.3% margin vs $3.66
    Buffett fair value$5.19
    ✓Buffett+29.5% margin vs $3.66
    Munger fair value$0.93
    ✗Munger-293.5% margin vs $3.66
    Pabrai fair value$1.58
    ✗Pabrai-131.6% margin vs $3.66
    Ackman fair value$0.93
    ✗Ackman-293.5% margin vs $3.66
  • Efficiency25% pass✓ 2✗ 9▾

    6 of 8 flag ALTO's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio3.39
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-4.5%
    ✗Buffett> 10%
    ROIC - WACC-14.5%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)8.7%
    ✗Greenblatt> 25%
    Current Ratio Change YoY2.65 -> 2.64
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY2.40x -> 2.36x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities3.39
    ✓Dreman> 1.5
    Return on Invested Capital6.1%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-5.1%; FY2024: ROIC=-12.6%; FY2025: ROIC=1.8%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC1.8% (RR=100% x ROIC=1.8%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest 1.8%)
    ✗SleepROIC > 12% in a majority of years
  • Verdicts38% pass✓ 6✗ 10▾

    Split decision: 9 FAIL · 5 PASS · 1 BUY · 1 NEUTRAL

    Overall verdict
    ✓GrahamPASS (4/9)✗BuffettFAIL (0/9)✗LynchFAIL (4/7)✗GreenblattRank #1139✓PiotroskiPASS (F-Score 5)✗DremanFAIL (4/11)✓MungerPASS (2/4)✗PabraiFAIL (1/3)✗AkreFAIL (2/6)✗MarksFAIL (3/5)✓AckmanPASS (4/9)✓TempletonPASS (4/8)✗SleepFAIL (1/6)✓AsnessBUY (Rank #143/2370 (Top 6.0%))✗NeffFAIL (2/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Chemicals
SIC Sector: Chemicals & Pharmaceuticals
Size: Micro Cap($283.9M)
Revenue: $917.9M-4.9% YoY
Net Income: $13.3M+122.6% YoY

Financial Snapshot

Operating Margin0.8%
Return on Equity5.4%
Debt / Equity0.32
Current Ratio2.64
EPS (Diluted)$0.16
Shares Retired−0.9% / −2.1% 2y

Similar Companies

CTA-PBEIDP, Inc.
$46.8B
CFCF Industries Holdings, Inc.
$18.3B
RPMRPM INTERNATIONAL INC/DE/
$13.2B
ESIElement Solutions Inc
$8.0B

Shareholder Return

Fiscal 2025

Issued 0.9% of shares last year, 2.1% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-03-13
FY 2024
Sources
  • 10-K · 2025-03-13
FY 2023
Sources
  • 10-K · 2024-03-14
FY 2022
Sources
  • 10-K · 2023-03-14
FY 2021
Sources
  • 10-K · 2024-03-14
Market Cap$283.9Mcurrent------$193.2Mest.$124.9Mest.$139.3Mest.$254.7Mest.$381.9Mest.
Revenue$960.2M↑4%$257.9M↑7%$245.7M↑12%$224.7M↓1%$917.9M↓5%$965.3M↓21%$1.2B↓8%$1.3B↑11%$1.2B
Operating Income$25.6M↑165%$7.0M↓59%$8.6M↑206%$2.5M↑128%$7.4M↑114%-$51.7M↓117%-$23.8M↑61%-$61.4M↓253%$40.1M
Net Income$50.8M↑201%$13.0M↓8%$11.7M↑206%$4.3M↑137%$13.3M↑123%-$59.0M↓111%-$28.0M↑33%-$41.6M↓190%$46.1M
EPS (Diluted)--$0.16↓16%$0.15↑200%$0.05↑131%$0.16↑120%$-0.82↓105%$-0.40↑33%$-0.60↓198%$0.61
Gross Margin5.8%↑192%5.7%↓41%6.8%↑864%4.1%↑614%3.8%↑278%1.0%↓21%1.3%↑162%-2.1%↓137%5.6%
Operating Margin2.7%↑163%2.7%↓61%3.5%↑195%1.1%↑128%0.8%↑115%-5.4%↓175%-2.0%↑58%-4.6%↓238%3.3%
ROE18.6%↑182%———5.4%↑121%-26.2%↓162%-10.0%↑26%-13.5%↓201%13.3%
Total Debt$58.1M↓45%$58.1M↓45%$64.5M↓48%$77.6M↓34%$79.6M↓20%$99.7M↑10%$90.7M↑16%$78.1M↑55%$50.4M
Shareholders' Equity$273.5M↑23%$273.5M↑23%$259.9M↑25%$249.9M↑17%$245.2M↑9%$225.1M↓19%$279.6M↓9%$308.1M↓11%$345.2M
Current Ratio3.39↓5%3.39↓5%3.19↓9%3.81↑32%2.642.65↑2%2.59↑1%2.55↓23%3.30
Debt / Equity0.21↓55%0.21↓55%0.25↓58%0.31↓43%0.32↓27%0.44↑37%0.32↑28%0.25↑74%0.15
Operating Cash Flow$55.1M↑1005%$12.9M↓44%$28.5M↑3458%$4.2M↑123%$13.2M↑476%-$3.5M↓116%$22.0M↑264%$6.0M↓77%$26.8M
Free Cash Flow$37.3M↑472%$8.5M↓60%$17.9M↑1444%$3.3M↑118%$8.6M↑159%-$14.6M↓94%-$7.5M↑76%-$31.7M↓404%$10.4M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Chemicals

ALTO vs Peers — Financial Grading

Revenue$917.9MBottom 25%
Net Income$13.3MBottom 25%
ROE5.4%Bottom 25%
D/E0.32Top 25%
Op. Margin0.8%Bottom 25%
Curr. Ratio2.64Median
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
EIDP, Inc.CTA-PB$46.8B$54.21——————2/95/92/70/3F-Score 14/11
CF Industries Holdings, Inc.CF$18.3B$125.09$7.1B$1.8B37.2%0.6632.5%3.373/94/95/73/3F-Score 88/11
RPM INTERNATIONAL INC/DE/RPM$13.2B$103.73$7.9B$661.4M20.0%0.77—1.683/92/93/71/3F-Score 67/11
Element Solutions IncESI$8.0B$33.08$2.6B$190.8M7.1%0.6113.4%3.682/92/91/71/3F-Score 56/11
NEWMARKET CORPNEU$6.5B$709.19$2.7B$418.7M23.5%0.5020.0%2.534/96/92/71/3F-Score 55/11
HEXCEL CORP /DE/HXL$6.0B$79.46$1.9B$109.4M8.7%0.799.1%2.262/92/93/70/3F-Score 64/11
ICL Group Ltd.ICL$5.8B$4.52$7.2B$226.0M3.8%0.468.1%1.335/94/92/70/3F-Score 45/11
BALCHEM CORPBCPC$5.5B$173.14$1.0B$154.8M12.3%0.1320.2%2.072/94/92/71/3F-Score 95/11